ArticleJournal of virology2025
Reverse genetics rescue of sylvatic dengue viruses.
Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
There are an unknown number of sylvatic ("sylvan" = "of the forest") dengue viruses currently being sustained by nonhuman primates and mosquitoes in the forests of Africa and Asia. Humans are regularly infected with these viruses, occasionally resulting in small epidemics. One barrier to understanding sylvatic dengue virus biology is the scarcity of stocks available for study. While the full-length genome sequences of 28 sylvatic viruses exist on GenBank, accessible infectious stocks exist for only a handful of these. One way to overcome this obstacle is to rescue infectious virus stocks using reverse genetics. However, reverse genetic engineering of dengue viruses is notoriously difficult. Here, we optimize a reverse genetics method specifically for the rescue of sylvatic dengue virus stocks from sequence data. The key to our approach was the observation that mosquito cells, rather than mammalian cells, must be used to launch sylvatic dengue virus replication from assembled genomes. We demonstrate the success of this technique by rescuing seven sylvatic dengue viruses. With this unique collection, we then characterized the relative fitness of each virus strain on human, monkey, and mosquito cells. While mosquito cells are universally permissive for the growth of sylvatic dengue viruses, some sylvatic dengue virus strains showed significantly better replication in human and monkey cells than others. These sylvatic dengue virus strains may have a greater potential for human adaptation. IMPORTANCE: Given the enormous burden of the four human dengue viruses, which emerged from the sylvatic dengue virus reservoir, it is important that we consider the possibility of a new dengue virus emerging into the human population. Nonhuman primate species in Asia and Africa are suspected to be the natural reservoir hosts for sylvatic dengue viruses. Occasionally, these sylvatic dengue viruses infect humans, although there are few stocks of these viruses available for study in the lab. Here, we optimize a reverse genetics technique for sylvatic dengue viruses, and we rescue stocks of seven strains. With this method, theoretically, any sylvatic dengue virus sequence deposited on GenBank can be transformed into a high-titer infectious virus stock.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.